Mark Ferguson

Title: Mark Ferguson - Innovator in Cancer Treatment

Introduction

Mark Ferguson is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the use of modified viruses in conjunction with specific inhibitors to enhance therapeutic outcomes for patients.

Latest Patents

Mark Ferguson holds a patent for "Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer." This invention provides a composition that includes a phosphatidylinositol 3-kinase (PI3K) inhibitor and a modified virus. The composition is designed for separate, subsequent, or simultaneous use in cancer treatment, with the modified virus intended for intravenous administration. He has 1 patent to his name.

Career Highlights

Mark Ferguson is affiliated with the University of London, where he conducts his research. His work has been instrumental in advancing the understanding of how to effectively deliver therapeutic agents to combat cancer. His innovative approach combines molecular biology with virology, paving the way for new treatment modalities.

Collaborations

Some of his notable coworkers include Yaohe Wang and Nicholas R. Lemoine. Their collaborative efforts contribute to the ongoing research and development in the field of cancer therapies.

Conclusion

Mark Ferguson's contributions to cancer treatment through his innovative patent highlight the potential of combining modern science with therapeutic applications. His work continues to inspire advancements in medical research and treatment strategies.